Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Debu, Tripathy"'
Autor:
Funda Meric-Bernstam, Debu Tripathy, Bora Lim, Senthil Damodaran, Hui Chen, Qingqing Ding, Aysegul A. Sahin, Weiwei Chen, Rajyalakshmi Luthra, Sarina Anne Piha-Paul
Publikováno v:
Human Pathology. 92:32-38
Summary HER2 mutations have been reported in approximately 2% of breast cancers. Regardless of HER2 overexpression or amplification status, breast cancer with HER2 mutations may respond to HER2-targeted therapy. As HER2 mutation is rare, the clinical
Autor:
Sandra M. Swain, Vincent Antao, Haocheng Li, Debu Tripathy, Joyce O'Shaughnessy, Laura Chu, Ginny Mason, Peter A. Kaufman, Denise A. Yardley, Sara A. Hurvitz, Mohammad Jahanzeb, Adam Brufsky, Hope S. Rugo, Melody A. Cobleigh
Publikováno v:
The oncologist, vol 25, iss 2
The Oncologist
The Oncologist
Background Limited data exist describing real‐world treatment of de novo and recurrent HER2‐positive metastatic breast cancer (MBC). Materials and Methods The Systemic Therapies for HER2‐Positive Metastatic Breast Cancer Study (SystHERs) was a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f85b6f5b4b0427599690acf0ecde9c9
https://escholarship.org/uc/item/3141135z
https://escholarship.org/uc/item/3141135z
Autor:
Haocheng Li, Ginny Mason, Denise A. Yardley, Sara A. Hurvitz, Melody A. Cobleigh, Sandra M. Swain, Adam Brufsky, Hope S. Rugo, Mohammad Jahanzeb, Peter A. Kaufman, Debu Tripathy, Vincent Antao, Laura Chu, Joyce O'Shaughnessy
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(8)
Purpose:Patients with HER2-positive metastatic breast cancer (MBC) with central nervous system (CNS) metastasis have a poor prognosis. We report treatments and outcomes in patients with HER2-positive MBC and CNS metastasis from the Systemic Therapies
Autor:
Bongin Yoo, Musa Mayer, Jessica F. Magidson, M. Ulcickas Yood, Debu Tripathy, Cheng Quah, Peter A. Kaufman, Adam Brufsky, Hope S. Rugo, Denise A. Yardley
Publikováno v:
British journal of cancer, vol 110, iss 11
British Journal of Cancer
British Journal of Cancer
Background: Data characterising long-term survivors (LTS) with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer (MBC) are limited. This analysis describes LTS using registHER observational study data. Methods: A lat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8007202333dc6ee996f826c845e57eb8
https://escholarship.org/uc/item/3q69g6zm
https://escholarship.org/uc/item/3q69g6zm